T: +44 (0)114 222 2261
Scientists from the University of Sheffield have been awarded £1.2 million to develop a drug to protect dopamine-producing brain cells and slow down the progression of Parkinson’s Disease.
Research from the Sheffield Institute for Translational Neuroscience (SITraN) suggests that routine genetic testing may be appropriate for all MND patients and could impact disease subclassification and clinical care.
Officially unveiled by Her Majesty The Queen in November 2010, the University of Sheffield’s Institute for Translational Neuroscience (SITraN) is unlike any other in the world. We are taking a look back at a decade of advances in neuroscience whilst looking to the future of research in Sheffield.
Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted therapy for motor neurone disease (MND) into clinical trials.
The University of Sheffield with Sheffield Teaching Hospitals NHS Foundation Trust is the only site in the UK to have participated in an international clinical trial for an investigational drug in people with a form of motor neurone disease (MND)